Krystal Biotech
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2015-01-01
- Employees
- 229
- Market Cap
- $5.6B
- Website
- http://www.krystalbio.com
- Introduction
Krystal Biotech, Inc. engages in developing and commercializing pharmaceutical products. It offers the product, VYJUVEK. The company was founded by Krish S. Krishnan and Suma M. Krishnan on April 15, 2016 and is headquartered in Pittsburgh, PA.
A Phase I Study of KB301, a Replication-Incompetent, Non-Integrating Vector Expressing Human Type III Collagen (COL3) for the Treatment of Superficial Skin Depressions
- Conditions
- WrinkleFine LinesSkin RoughnessSkin Thickness
- Interventions
- Other: Placebo
- First Posted Date
- 2020-09-07
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Krystal Biotech, Inc.
- Target Recruit Count
- 85
- Registration Number
- NCT04540900
- Locations
- 🇺🇸
Aesthetx, Campbell, California, United States
🇺🇸Steve Yoelin, MD Medical Associates, Inc., Newport Beach, California, United States
🇺🇸Mission Dermatology, Rancho Santa Margarita, California, United States
Ph 3 Efficacy and Safety of B-VEC for the Treatment of DEB
- Conditions
- Dystrophic Epidermolysis BullosaDominant Dystrophic Epidermolysis BullosaRecessive Dystrophic Epidermolysis Bullosa
- Interventions
- Other: PlaceboBiological: Topical Beremagene Geperpavec
- First Posted Date
- 2020-07-29
- Last Posted Date
- 2023-02-17
- Lead Sponsor
- Krystal Biotech, Inc.
- Target Recruit Count
- 31
- Registration Number
- NCT04491604
- Locations
- 🇺🇸
Mission Dermatology Center, Rancho Santa Margarita, California, United States
🇺🇸Stanford University, Stanford, California, United States
🇺🇸Pediatric Skin Research, LLC, Coral Gables, Florida, United States
The Natural History of Wounds in Patients With Dystrophic Epidermolysis Bullosa (DEB)
- Conditions
- Dystrophic Epidermolysis BullosaDEB - Dystrophic Epidermolysis Bullosa
- First Posted Date
- 2019-12-30
- Last Posted Date
- 2021-09-17
- Lead Sponsor
- Krystal Biotech, Inc.
- Registration Number
- NCT04214002
- Locations
- 🇺🇸
Stanford University, Redwood City, California, United States
Topical KB105 Gene Therapy for the Treatment of TGM1-deficient Autosomal Recessive Congenital Ichthyosis (ARCI)
- Conditions
- TGM-1 Related Autosomal Recessive Congenital Ichthyosis
- Interventions
- Biological: KB105
- First Posted Date
- 2019-08-07
- Last Posted Date
- 2021-09-13
- Lead Sponsor
- Krystal Biotech, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT04047732
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸Paddington Testing Company, Inc., Philadelphia, Pennsylvania, United States
A Phase I/II Study of KB103, a Topical HSV1-COL7, on DEB Patients
- Conditions
- Dystrophic Epidermolysis Bullosa
- Interventions
- Biological: Topical beremagene geperpavecBiological: Placebo gel
- First Posted Date
- 2018-05-24
- Last Posted Date
- 2023-01-31
- Lead Sponsor
- Krystal Biotech, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT03536143
- Locations
- 🇺🇸
Stanford University, Stanford, California, United States